Stay updated with breaking news from Thomas Biegi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN)
National Comprehensive Cancer Network® Updates Designation of Monjuvi® to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas BOSTON,... | March 15, 2022
Conference Call AlertPLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR);(NASDAQ:MOR) will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm CET
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 24, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) was acknowledged as a Best Practice Leader in the European Women on Boards' Gender Equality Index Report, ranking
Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million ( € 66.9 million)Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 millionPLANEGG / MUNICH, GERMANY / ACCESSWIRE